LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・CytoSorbents Corp

CytoSorbents Corp

Closed

SectorHealthcare

0.44 2.33

Buy Sell

Overview

Share price change

24h

Current

Min

0.43

Max

0.45

Key metrics
By Trading Economics
Income	368K -5.1M
Sales	-370K 8.9M
EPS	-0.08
Profit margin	-57.863
Employees	129
EBITDA	648K -3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+63.04% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-9.5M 30M
Previous open	-1.89
Previous close	0.44

News Sentiment

By Acuity

46%

54%

135 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.705 / 0.771 Support & Resistance

CytoSorbents Corp Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 May 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 May 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 May 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 May 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 May 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 May 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 May 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 May 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 May 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 May 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 May 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 May 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 May 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 May 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 May 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 May 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 May 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 May 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 May 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 May 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 May 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 May 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 May 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 May 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 May 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

63.04% upside

12 Months Forecast

Average 0.75 USD 63.04%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

All events are bearish.

Sentiment

By Acuity

135 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.